Javascript must be enabled to continue!
Determinants of IGF‐I status in a large cohort of growth hormone‐deficient (GHD) subjects: the role of timing of onset of GHD
View through CrossRef
Summarybackground IGF‐I standard deviation score (SDS) is widely used in clinical practice; however, factors determining IGF‐I SDS in GH‐deficient (GHD) individuals remain incompletely understood. Earlier studies have been limited by the small size of cohorts studied. We have used the KIMS database to examine if a true difference exists between subjects who developed GHD in adult life (AO), and those who developed GHD in childhood (CO).patients A total of 1317 patients fulfilled the inclusion criteria, 1073 with AO GHD and 244 with CO GHD.methods Serum IGF‐I concentrations were determined by a hydrochloric acid–ethanol extraction radioimmunoassay method using synthetic IGF‐I for labelling. The reference range was calculated using normative data from healthy Swedish individuals.results A total of 86% of patients with CO GHD but only 52% of patients with AO GHD had IGF‐I SDS below −2 SDS. The CO cohort had a lower IGF‐I SDS (−4·69 vs.−2·24, P < 0·0001), a smaller body mass index (BMI; 26·6 vs. 28·6 kg/m2, P < 0·0001) and waist–hip ratio (WHR; 0·90 vs. 0·92 P < 0·001) than the AO cohort. A stepwise multiple linear regression was performed to examine the principal determinants of IGF‐I SDS. Age at onset of GHD was the most important determinant of IGF‐I SDS, contributing 17% towards the variability of IGF‐I SDS. Timing of onset, gender, BMI, and number of pituitary hormone deficiencies other than GH deficiency were also significant determinants of IGF‐I SDS.conclusion Whilst age at onset of GHD was the most important determinant of IGF‐I SDS, individuals with CO GHD had values on average 1·43 lower than those with AO GHD, all other factors being equal. Potential explanations include differences in GH secretory patterns, variation in body composition, and/or suboptimal treatment of GHD in childhood.
Title: Determinants of IGF‐I status in a large cohort of growth hormone‐deficient (GHD) subjects: the role of timing of onset of GHD
Description:
Summarybackground IGF‐I standard deviation score (SDS) is widely used in clinical practice; however, factors determining IGF‐I SDS in GH‐deficient (GHD) individuals remain incompletely understood.
Earlier studies have been limited by the small size of cohorts studied.
We have used the KIMS database to examine if a true difference exists between subjects who developed GHD in adult life (AO), and those who developed GHD in childhood (CO).
patients A total of 1317 patients fulfilled the inclusion criteria, 1073 with AO GHD and 244 with CO GHD.
methods Serum IGF‐I concentrations were determined by a hydrochloric acid–ethanol extraction radioimmunoassay method using synthetic IGF‐I for labelling.
The reference range was calculated using normative data from healthy Swedish individuals.
results A total of 86% of patients with CO GHD but only 52% of patients with AO GHD had IGF‐I SDS below −2 SDS.
The CO cohort had a lower IGF‐I SDS (−4·69 vs.
−2·24, P < 0·0001), a smaller body mass index (BMI; 26·6 vs.
28·6 kg/m2, P < 0·0001) and waist–hip ratio (WHR; 0·90 vs.
0·92 P < 0·001) than the AO cohort.
A stepwise multiple linear regression was performed to examine the principal determinants of IGF‐I SDS.
Age at onset of GHD was the most important determinant of IGF‐I SDS, contributing 17% towards the variability of IGF‐I SDS.
Timing of onset, gender, BMI, and number of pituitary hormone deficiencies other than GH deficiency were also significant determinants of IGF‐I SDS.
conclusion Whilst age at onset of GHD was the most important determinant of IGF‐I SDS, individuals with CO GHD had values on average 1·43 lower than those with AO GHD, all other factors being equal.
Potential explanations include differences in GH secretory patterns, variation in body composition, and/or suboptimal treatment of GHD in childhood.
Related Results
The impact of idiopathic childhood‐onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD
The impact of idiopathic childhood‐onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD
Summaryobjective Despite seemingly adequate growth hormone (GH) treatment during childhood, children with GH deficiency (GHD) have reduced bone mineral density (BMD) at final heig...
The Growth Hormone Deficiency (GHD) Reversal Trial: Effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD – A non-inferiority randomised controlled trial (RCT).
The Growth Hormone Deficiency (GHD) Reversal Trial: Effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD – A non-inferiority randomised controlled trial (RCT).
Abstract
The GHD Reversal trial is a non-inferiority RCT (ISRCTN12552768) funded by the NIHR HTA Programme (NIHR127468)
Background: Growth hormone deficiency (GHD) is the c...
Estrogen and IGF-I Independently Down-Regulate Critical Repressors of Breast Cancer Growth.
Estrogen and IGF-I Independently Down-Regulate Critical Repressors of Breast Cancer Growth.
Abstract
Background: Estrogen receptor and insulin-like growth factor (IGF) signaling pathways are important for both normal mammary gland development and breast can...
Retrospective analysis of early growth patterns in children diagnosed growth hormone deficient during childhood.
Retrospective analysis of early growth patterns in children diagnosed growth hormone deficient during childhood.
This retrospective study examines early growth patterns in children diagnosed with Growth Hormone Deficiency (GHD) during childhood. It highlights the significance of early detecti...
The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study
The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study
Increased cardiovascular morbidity and mortality were reported in GH deficiency (GHD), and GH replacement can ameliorate cardiac abnormalities of adult GHD patients. To test the po...
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy
OBJECTIVE: Ghrelin stimulates growth hormone (GH) secretion both in vivo and in vitro. Ghrelin is mainly produced in and released from the stomach but it is probably also produced ...
Toward a comprehensive neurobiology of IGF‐I
Toward a comprehensive neurobiology of IGF‐I
AbstractInsulin‐like growth factor I (IGF‐I) belongs to an ancient family of hormones already present in early invertebrates. The insulin family is well characterized in mammals, a...
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
GH secretion was reevaluated after completion of GH treatment at a mean age of 19.2 ± 3.2 yr in 35 young adults with childhood-onset GH deficiency (GHD). The patients were subdivid...


